Leading the Fight Against
Swine Viruses
AI-Driven Vaccine &
Antibody Development
OUR STORY
At Kermode Biotechnologies, we are dedicated to pioneering comprehensive solutions in animal health, with a focus on combating critical viral threats including African Swine Fever Virus (ASFV), Seneca Virus A, and Swine Influenza. Founded on the principles of innovation and scientific excellence, our team is developing novel vaccines that leverage unique protein antigen subunits to elicit strong immune responses in swine. With roots in both Denver, Colorado and Shenzhen, China, we bridge the gap between cutting-edge research and practical applications. Our mission is to safeguard global swine populations, enhance food security, and support farmers worldwide. Through relentless pursuit of groundbreaking research, Kermode Biotechnologies stands at the forefront of animal disease prevention, transforming challenges into opportunities for a healthier future.
AFRICAN SWINE FEVER VIRUS (ASFV)
​
The spread ASFV has devastated the commercial swine industries in Europe, Russia, and most recently China, resulting in billions of lost dollars and the loss of a major nutritional staple. It is a matter of time before ASFV infiltrates North American livestock.
ASFV is a highly contagious
viral pathogen that swiftly
infects swine livestock.
Once the swine are infected, the virus
will kill the animal within 24 to 48 hours.
The mortality rate for
ASFV-infected animals is 100%.
SENECA VIRUS A (SVA)
​
The emergence of Seneca Virus A has disrupted swine operations across North America, causing substantial economic losses through reduced productivity and increased mortality. With its highly contagious nature, Seneca Virus A poses an escalating threat to commercial pork production, jeopardizing both industry profitability and protein security. There is currently no commercial vaccine for SVA
Increase in SVA detection globally between 2015 and 2024, highlighting its emerging importance as a transboundary animal disease.
SVA causes open sores, blisters and negatively affects reproduction, making infected swine herds undesirable for market.
Our vaccine demonstrates nearly 100% efficacy in early challenge models, outperforming other SVA vaccines.
SWINE INFLUENZA VIRUS (SIV)
​
The emergence of Swine Influenza Virus continues to disrupt swine operations worldwide, causing substantial economic losses through reduced productivity and increased mortality. With its highly contagious nature and rapid mutation ability, SIV threatens global pork production while increasing the risk of zoonotic transmission to humans. Current vaccines struggle to keep pace with viral evolution, leaving producers vulnerable to new strains and potential pandemic threats.
SIV rapidly and unpredictably mutates into new strains
Infected swine herds often experience 100% morbidity from SIV
Vaccinating pigs helps prevent swine flu from jumping to humans.
OUR APPROACH
We use machine learning combined with wet biochemistry to identify weak points in how viruses reproduce and create modified versions of key viral proteins called "toxoids" that train the immune system to fight the real virus. For African Swine Fever, we use two methods: purified toxoid mixtures and a delivery system that presents multiple targets at once. Our Swine Influenza vaccine focuses on parts of the virus that are more resistant to mutation, providing broader protection against viral variants. For Senecavirus A, we use a specially weakened virus that's inherently safer due to SVA's naturally limited pathogenicity. Each approach is designed to provide strong, lasting protection while maintaining safety for livestock.
TOXOID
COMMERCIAL
DEVELOPMENT PIPELINE
Pre-Clinical
Immune Responses
Early Challenge
Late Challenge
Seneca Valley A (SVA) Vaccine
Swine Influenza Virus Vaccine
ASFV Toxoid Orf Vaccine
ASFV Toxoid Antigen Vaccine
ASFV Antibody Therapeutic
COLLABORATORS
At Kermode Biotechnologies, we believe in the power of collaboration to drive innovation and success. Our partners play a fundamental role in advancing our mission to develop cutting-edge solutions for the prevention and control of critical swine pathogens, including the African Swine Fever Virus (ASFV), Seneca Virus A (SVA), and Swine Influenza Virus (SIV). By working together, we leverage each other's strengths, expertise, and resources to accelerate the development and distribution of our groundbreaking vaccine technologies.
Through strategic partnerships with leading research institutions, biotechnology companies, and regulatory agencies, we are advancing innovative vaccine solutions that address these interconnected viral threats. Our collaborative approach enables us to develop synergistic strategies across multiple disease platforms while streamlining manufacturing processes for our comprehensive swine health portfolio.
KERMODE BIOTECHNOLOGIES IN THE NEWS
June 3rd, 2024 - Kermode to Present at the Kansas City Animal Health Corridor Summit - August 26th - 27th, 2024
Feb. 4th, 2023 - Kermode Enters into Receptor Discovery Agreement with Dual Biosystems AG
